Fig. 1: Identification of drugs combats abiraterone resistance using a high-throughput assay.

A LNCaP/ABI cells were seeded in 96 wells and treated for 24 h with an FDA-approved drug library, including 1815 drugs (n = 2). Cell viability was determined by CCK-8 assay. B C4-2/ABI and 22RV1/ABI cells were treated with the six drugs (i.g. Otilonium, Idarubicin, Auranofin, Sitafloxacin, Pyrvinium pamoate, and Erdafitinib) for 24 h. Cell viability was determined by CCK-8 assay. The Venn diagram indicates that IDA is a candidate drug for overcoming abiraterone resistance in LNCaP/ABI, C4-2/ABI, and 22RV1/ABI cells. C–F Abiraterone-resistant cell lines (LNCaP/ABI, 22RV1/ABI, and C4-2/ABI), the parental control cell lines (LNCaP, 22RV1, and C4-2), and RWPE-1 cells were treated with DMSO, IDA, ABI, or a combination of ABI and IDA for 24 h. Cell viability was determined by the CCK-8 assay (n = 6). G–I Abiraterone-resistant cell lines (LNCaP/ABI, 22RV1/ABI, and C4-2/ABI), the parental control cell lines (LNCaP, 22RV1, and C4-2), and RWPE-1 cells were treated with indicated concentration (i.g., 0 μΜ, 0.01 μΜ, 0.1 μΜ, 0.5 μΜ, 1 μΜ, 2 μΜ, 5 μΜ, 10 μΜ, 20 μΜ) in the presence of abiraterone (10 μΜ) for 24 h. Cell viability was determined by CCK-8 assay(n = 6). IC₅₀ was determined by dose-response curves. Data are presented as means ± s.e.m. The asterisks indicate significant differences (two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.01).